4//SEC Filing
Kwon Paul 4
Accession 0000899243-19-029192
CIK 0001566044other
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 9:59 PM ET
Size
7.0 KB
Accession
0000899243-19-029192
Insider Transaction Report
Form 4
Kwon Paul
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common stock
2019-12-11+80,300→ 80,300 total - Tax Payment
Common stock
2019-12-11$4.52/sh−27,766$125,502→ 52,534 total
Footnotes (1)
- [F1]On July 29, 2019, the Reporting Person was granted 80,300 restricted stock units, ("RSUs"), for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs were scheduled to vest in two (2) equal annual installments beginning July 29, 2020. The vesting of the RSUs was accelerated in full on December 11, 2019 in connection with the pending transactions contemplated by the Agreement and Plan of Merger entered into on November 10, 2019 among the Issuer, Foamix Pharmaceuticals Ltd and Giants Merger Subsidiary Ltd., a wholly-owned subsidiary of the Issuer, in order to mitigate potential negative tax consequences to both the Issuer and the Reporting Person under Section 280G and 4999 of the Internal Revenue Code.
Documents
Issuer
Menlo Therapeutics Inc.
CIK 0001566044
Entity typeother
Related Parties
1- filerCIK 0001727717
Filing Metadata
- Form type
- 4
- Filed
- Dec 12, 7:00 PM ET
- Accepted
- Dec 13, 9:59 PM ET
- Size
- 7.0 KB